Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.

The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:

##STR00001## wherein R.sub.1 is

##STR00002## wherein at least one of H.sub.1, H.sub.2 or H.sub.3 is a deuterium-enriched —H site, or

##STR00003## wherein at least one of H.sub.1, H.sub.2, H.sub.3, H.sub.4 or H.sub.5 is a deuterium-enriched —H site,
or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.

The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:

##STR00001## wherein R.sub.1 is

##STR00002## wherein at least one of H.sub.1, H.sub.2 or H.sub.3 is a deuterium-enriched —H site, or

##STR00003## wherein at least one of H.sub.1, H.sub.2, H.sub.3, H.sub.4 or H.sub.5 is a deuterium-enriched —H site,
or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) through reduced cell and blood concentration of ceramides.

The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) through reduced cell and blood concentration of ceramides.

The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α.sub.1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as α.sub.1-antitrypsin deficiency (A1AD or AATD).

The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α.sub.1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as α.sub.1-antitrypsin deficiency (A1AD or AATD).

The invention relates to compound shown with formula (I) for a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.

##STR00001##